Vitamin D3 + K2

Approximately 40-60% of US adults have 25(OH)D below 30 ng/mL based on NHANES data, making this one of the most prevalent nutritional deficiencies in the modern world. High-risk groups include: >40° latitude residents from October through March (insufficient UVB for cutaneous synthesis), people with dark skin (higher melanin reduces UVB penetration, requiring 3-6x longer sun exposure), indoor workers or those who consistently cover skin outdoors, individuals with BMI >30 (D3 sequesters in adipose tissue reducing bioavailability by ~20-30%), post-menopausal women, adults over 65, and anyone taking medications that accelerate D3 catabolism (rifampin, anticonvulsants, glucocorticoids). The definitive test is serum 25(OH)D -- do not guess by symptoms alone. Lab target: 40-60 ng/mL. Below 20 ng/mL is frank deficiency; 20-30 ng/mL is insufficiency. Even if you get some sun, testing is the only reliable way to confirm status.

D3 increases intestinal calcium absorption -- necessary for bone mineralization, but only if that calcium ends up in bone matrix rather than arterial walls. K2 activates two critical proteins that direct calcium appropriately: osteocalcin (via carboxylation, drives calcium into bone) and Matrix Gla Protein or MGP (carboxylated MGP is the most potent known inhibitor of arterial calcification). Without adequate K2, D3-driven hypercalciuria and vascular calcification risk may theoretically increase. The Rotterdam cohort (Geleijnse 2004) showed dietary K2 -- not K1 -- associated with 57% lower CV mortality and 52% lower aortic calcification. K2 supplementation alone (Knapen 2015, MK-7 180 mcg/day, 3 years) significantly reduced arterial stiffness and improved bone density markers in postmenopausal women. The combination is more physiologically complete than D3 alone.

NO -- not without explicit supervision from your anticoagulation clinic or prescribing physician. Warfarin (Coumadin) works by inhibiting vitamin K-dependent clotting factor synthesis. K2 supplementation directly counters this mechanism and can drop your INR out of therapeutic range, increasing clotting and thromboembolism risk. This is not a theoretical interaction -- it is pharmacologically certain and well-documented. If you are on warfarin and want to supplement vitamin D, use D3 alone (no K2) and inform your prescriber. If you are on newer oral anticoagulants (apixaban/Eliquis, rivaroxaban/Xarelto, dabigatran/Pradaxa), these work by different mechanisms and do NOT interact with vitamin K, but confirm with your pharmacologist before adding any supplement. Do not rely on supplement label disclosures -- they are often inadequate for this interaction.

Test first, then dose. The sophisticated protocol: get a baseline 25(OH)D via GrassrootsHealth home kit ($65-75) or standard lab, then dose accordingly. If 25(OH)D <20 ng/mL (frank deficiency): 5,000-10,000 IU D3/day + 100-200 mcg MK-7, retest at 8-12 weeks, then drop to maintenance. If 25(OH)D 20-30 ng/mL: 3,000-5,000 IU/day and retest at 12 weeks. If 25(OH)D 30-50 ng/mL: 1,000-3,000 IU/day. Target is 40-60 ng/mL -- neither deficient nor potentially hypercalcemic. Without testing, most adults at >40° latitude need 2,000-4,000 IU/day to maintain adequacy year-round; this is conservative and safe for most people. The FDA UL of 4,000 IU/day is considered overly conservative by the Endocrine Society, which cites 10,000 IU/day as the clinical safe upper limit. Never dose above 10,000 IU/day chronically without medical monitoring of serum calcium and 25(OH)D.

Both forms carboxylate osteocalcin and MGP, but their pharmacokinetics differ substantially. MK-7 (menaquinone-7, derived from natto fermentation) has a half-life of 3 days, produces sustained serum levels, and works at 100-200 mcg once-daily. This is the practical standard for most supplementation protocols. MK-4 (menaquinone-4, synthetic) has a 1-2 hour half-life; the Japanese osteoporosis dose is 45 mg/day (45,000 mcg) divided 3x/day -- a 300-450x higher mass dose than MK-7. At typical supplement doses of 1,000-5,000 mcg MK-4, you are probably undertreating because the serum residence time is too short for consistent carboxylation. Most biohacker and clinical protocols use MK-7. The exception: very high-dose Japanese-protocol MK-4 for established osteoporosis in a supervised setting. Both forms have the same warfarin interaction.

The evidence is strongest in deficient elderly populations. Bischoff-Ferrari 2009 meta-analysis: D3 + calcium reduced falls by 19% and hip fractures by 26% in community-dwelling elderly, with strongest effects at 800 IU/day supplemental D. The USPSTF recommends D+calcium for community-dwelling postmenopausal women with deficiency. Japanese trials with high-dose MK-4 (45 mg/day) showed significant fracture risk reduction. Knapen 2015 used MK-7 180 mcg/day for 3 years in healthy postmenopausal women: significantly improved carboxylated osteocalcin (bone formation marker), reduced undercarboxylated osteocalcin, and statistically significant improvement in arterial stiffness. The combination protocol is more complete than either alone. Important caveat: VITAL (Manson 2019, 2,000 IU/day over 5.3 years) did not show fracture reduction in a general healthy adult population -- the bone benefits concentrate in deficient individuals, not already-adequate adults.

Toxicity is real but requires sustained high doses without monitoring. Vieth 2007 (PMID 17209171) placed the toxicity threshold at >10,000 IU/day sustained or serum 25(OH)D >150 ng/mL. Symptoms of hypervitaminosis D: hypercalcemia (nausea, vomiting, weakness), polyuria, nephrolithiasis (kidney stones), and in severe cases, AKI. At 4,000 IU/day (FDA UL), toxicity is essentially unheard of in otherwise healthy adults. At 10,000 IU/day, toxicity is rare with normal renal function and adequate hydration. At biohacker protocols of 20,000-50,000 IU/day without monitoring, risk becomes significant. Individuals at elevated risk for toxicity: primary hyperparathyroidism (hypercalcemia independent of D), granulomatous diseases (sarcoidosis, TB, some lymphomas -- these produce calcitriol autonomously), and those taking thiazide diuretics (reduces urinary calcium excretion). If in doubt, test: serum 25(OH)D, corrected calcium, and parathyroid hormone (PTH) with any dose above 5,000 IU/day.

Promising signal, not proven prevention. VITAL (Manson 2019, n=25,871, 2,000 IU/day): null for overall cancer incidence at 5.3 years, but 25% reduction in cancer mortality after 2+ years of follow-up (HR 0.75, 95% CI 0.59-0.96). The lag to cancer mortality benefit suggests the intervention may affect progression and metastasis more than initiation. VITAL cancer substudy data also showed a 17% reduction in metastatic or fatal cancer. Bjelakovic 2014 Cochrane (56 RCTs, n=95,286): D3 associated with 6% overall mortality reduction (RR 0.94), consistent with a cancer-mortality component. No single cancer type is robustly prevented; colorectal, breast, and pancreatic cancers have the strongest observational signals. Bottom line: adequate D status (not megadosing) is associated with lower cancer mortality in a multi-year RCT. This is not a substitute for screening or treatment.